Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort

ABSTRACT: microRNAs are small, non-coding, single-stranded RNAs between 18-22 nucleotides long that regulate gene expression. Expression of microRNAs is altered in tumor compared to normal tissue; there is some evidence that these changes may be reflected in the serum of cancer cases compared to healthy individuals. This has yet to be examined in a prospective study where samples are collected before diagnosis. We used Affymetrix arrays to examine serum miRNA expression profiles in 410 participants in the Sister Study, a prospective cohort study of 50,884 women. All women in the cohort had never been diagnosed with breast cancer at the time of enrollment.

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE44281 | GEO | 2013/05/08

SECONDARY ACCESSION(S): PRJNA189285

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort

Project description:microRNAs are small, non-coding, single-stranded RNAs between 18-22 nucleotides long that regulate gene expression. Expression of microRNAs is altered in tumor compared to normal tissue; there is some evidence that these changes may be reflected in the serum of cancer cases compared to healthy individuals. This has yet to be examined in a prospective study where samples are collected before diagnosis. We used Affymetrix arrays to examine serum miRNA expression profiles in 410 participants in the Sister Study, a prospective cohort study of 50,884 women. All women in the cohort had never been diagnosed with breast cancer at the time of enrollment. We compared global miRNA expression patterns in 205 women who subsequently developed breast cancer and 205 women who remained breast cancer-free.

2013-05-08 | E-GEOD-44281 | biostudies-arrayexpress

Epigenome-wide association study of breast cancer using prospectively collected sister study samples.

Project description: Not available

| S-EPMC3653821 | biostudies-other

MicroRNA markers for the diagnosis of pancreatic and biliary tract cancers

Project description:MicroRNAs from serum samples could detect pancreatic and biliary tract cancer patients more accurately than other traditional markers. Prospective miRNA markers for pancreatic/biliary tract cancer were selected in the training cohort. Using these miRNAs, discriminant analysis was performed, and the diagnostic accuracy, sensitivity and specificity were calculated in the test cohort.

2015-03-01 | E-GEOD-59856 | biostudies-arrayexpress

Five microRNAs in serum are able to differentiate breast cancer patients from healthy individuals

Project description:Breast Cancer is the cancer with most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients versus 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based upon the expression levels of 5 microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the over-expression and down-regulation of proteins differently expressed in the serum of breast cancer patients versus that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a-5p, mir-497-5p, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of mir-125b-5p, miR-29c-3p, mir-16-5p, miR-1260, and miR-451a was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of mir-16-5p with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and use of the predictor here described might be of potential importance for breast cancer prediction.

2020-09-18 | PXD020795 | Pride

Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort

Project description: Not available

| S-ECPF-GEOD-44281 | biostudies-other

Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort.

Project description: Not available

| S-EPMC3706791 | biostudies-literature

human serum: Control vs. patients with repeated implantation failure

Project description:microRNAs profiling of human serum comparing control fertile women with women who had experienced repeated implantation failure after ovarian stimulation and IVF-ET. Repeated implantation failure was defined as women who had undergone≥3 failed cycles with high-grade embryos were transferred.

2018-06-08 | GSE106307 | GEO

Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data

Project description:Alzheimer’s disease (AD) is the most common subtype of dementia, followed by Vascular Dementia (VaD), and Dementia with Lewy Bodies (DLB). Recently, microRNAs (miRNAs) have received a lot of attention as the novel biomarkers for dementia. Here, using serum miRNA expression of 1,601 Japanese individuals, we investigated potential miRNA bio- markers and constructed risk prediction models, based on a supervised principal component analysis (PCA) logistic regression method, according to the subtype of dementia. The final risk prediction model achieved a high accuracy of 0.873 on a validation cohort in AD, when using 78 miRNAs: Accuracy = 0.836 with 86 miRNAs in VaD; Accuracy = 0.825 with 110 miRNAs in DLB. To our knowledge, this is the first report applying miRNA-based risk pre- diction models to a dementia prospective cohort. Our study demonstrates our models to be effective in prospective disease risk prediction; and with further improvement may contribute to practical clinical use in dementia.

2019-02-26 | GSE120584 | GEO

Prospective cohort carriage study

Project description:Prospective cohort carriage study

| PRJEB53187 | ENA

Serum microRNA sequencing for diagnosis of invasive ovarian cancer

Project description:We constructed a heterogeneous patient cohort of pre-treatment (prior to either surgery or chemotherapy) blood samples from 180 women enrolled in two independent prospective cohort studies of women presenting with an adnexal mass. One sample (E-1056) was later excluded due to an abnormally high level of mir-122 believed to be due to a recent MI. The remaining 179 samples were subdivided 3:1 into a 135 patient training set and 44 patient validation set. Total serum RNA was extracted, converted into miRNA next generation sequencing libraries, and sequenced. The variables for classification model development were selected using three methods – a significance filter (using a student’s t-test ), a group-stratified fold change filter, and a correlation-based feature selection (CFS). We deployed 11 different machine learning algorithms on the three sets of variables to separate the cases of invasive cancer from the healthy controls or benign/borderline masses. The tools were graded in terms of receiver operating characteristic area under the curve (ROC AUC). The model was validated both by qPCR on the study samples as well as by external validation on an independent publicly available dataset of 454 patients with a range of diagnoses, including ovarian cancer. The qPCR signature was then externally validated on another independent external cohort.

2017-10-13 | GSE94533 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data